Having trouble accessing articles? Reset your cache.

NICE backs Esbriet for subgroup

The U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Esbriet pirfenidone from InterMune

Read the full 172 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE